Research Progress of PD-1/PD-L1 Targeted Radionuclide Molecular Probes in Tumor Immunotherapy
PD-1/PD-L1 immune checkpoint therapy has become another important treatment for several refractory and recurrent tumors besides radiotherapy and chemotherapy; however, only some patients can benefit from it. PD-1/PD-L1 targeted radionuclide molecular probe imaging can detect the PD-1/PD-L1 expressio...
Main Authors: | WANG Shujing, XU Xiaoxia, ZHOU Xin, LIU Teli, LI Nan, ZHU Hua, YANG Zhi |
---|---|
Format: | Article |
Language: | zho |
Published: |
Magazine House of Cancer Research on Prevention and Treatment
2020-01-01
|
Series: | Zhongliu Fangzhi Yanjiu |
Subjects: | |
Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2020.19.1123.htm |
Similar Items
-
Correlation Between PD-L1 Expression and 18F-FDG Uptake in Lung Adenocarcinoma
by: SONG Yufei, et al.
Published: (2019-11-01) -
Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01) -
Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
by: Kim A. Brogden, et al.
Published: (2018-02-01) -
Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters
by: Angelo Castello, et al.
Published: (2020-05-01) -
PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)